• Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.
    • Liberto JM, Chen SY, Shih IM, Wang TH, Wang TL, Pisanic TRR.
    • Cancers (Basel). 2022 Jun 11;14(12):2885. doi: 10.3390/cancers14122885.
    • Beyond the pill: contraception and the prevention of hereditary ovarian cancer.
    • Xia YY, Kotsopoulos J.
    • Hered Cancer Clin Pract. 2022 Jun 6;20(1):21. doi: 10.1186/s13053-022-00227-z.
    • Germline BRCA variants, lifestyle and ovarian cancer survival.
    • Gersekowski K, Delahunty R, Alsop K, Goode EL, Cunningham JM, Winham SJ, Pharoah P, Song H, Jordan S, Fereday S, DeFazio A, Friedlander M, Obermair A; OPAL Study Group; AOCS Group, Webb PM.>
    • Gynecol Oncol. 2022 Jun;165(3):437-445. doi: 10.1016/j.ygyno.2022.03.020. Epub 2022 Apr 7.
    • Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.
    • Park J, Huang D, Chang YJ, Lim MC, Myung SK.
    • Carcinogenesis. 2022 Apr 25;43(3):231-242. doi: 10.1093/carcin/bgab107.
    • Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
    • Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips KA, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA.
    • J Natl Cancer Inst. 2022 Apr 11;114(4):540-552. doi: 10.1093/jnci/djac004.

    Commentary:

    Oral Contraceptives and BRCA Cancer: A Balancing Act.

    • Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    • Xia YY, Gronwald J, Karlan B, Lubinski J, McCuaig JM, Brooks J, Moller P, Eisen A, Sun S, Senter L, Bordeleau L, Neuhausen SL, Singer CF, Tung N, Foulkes WD, Sun P, Narod SA, Kotsopoulos J; Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2022 Mar;164(3):514-521. doi: 10.1016/j.ygyno.2022.01.014. Epub 2022 Jan 19.
    • Predictors of cardiopulmonary fitness in cancer-affected and -unaffected women with a pathogenic germline variant in the genes BRCA1/2 (LIBRE-1).
    • Berling-Ernst A, Yahiaoui-Doktor M, Kiechle M, Engel C, Lammert J, Grill S, Dukatz R, Rhiem K, Baumann FT, Bischoff SC, Erickson N, Schmidt T, Niederberger U, Siniatchkin M, Halle M.
    • Sci Rep. 2022 Feb 21;12(1):2907. doi: 10.1038/s41598-022-06913-1.
    • Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status.
    • Logue CA, Pugh J, Foden P, Mahmood RD, Morgan RD, Mitchell C, Hasan J, Clamp AR, Jayson GC.
    • Sex Med. 2022 Feb;10(1):100465. doi: 10.1016/j.esxm.2021.100465. Epub 2021 Dec 15.
    • Healthy lifestyle, genetic risk, and incidence of cancer: A prospective cohort study of 13 cancer types.
    • Byrne S, Boyle T, Ahmed M, Lee SH, Benyamin B, Hyppönen E.
    • medRxiv. 2021 Dec 7. doi: 10.1101/2021.12.07.21267341. Unpublished preprint.

    News: Lifestyle Choices Can Influence Genetic Risks for Cancer. (Medscape Oncology)

    • Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1.
    • Neirich L, Yahiaoui-Doktor M, Lammert J, Basrai M, Seethaler B, Berling-Ernst A, Ramser J, Quante AS, Schmidt T, Niederberger U, Rhiem K, Schmutzler R, Engel C, Bischoff SC, Halle M, Kiechle M, Grill S.
    • Breast Cancer Res Treat. 2021 Dec;190(3):463-475. doi: 10.1007/s10549-021-06400-7. Epub 2021 Sep 27.
    • Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers.
    • Kim SJ, Lubinski J, Huzarski T, Møller P, Armel S, Karlan BY, Senter L, Eisen A, Foulkes WD, Singer CF, Tung N, Bordeleau L, Neuhausen SL, Olopade OI, Eng C, Weitzel JN, Fruscio R, Narod SA, Kotsopoulos J.
    • Cancer Epidemiol Biomarkers Prev. 2021 Aug 23:cebp.0296.2021. doi: 10.1158/1055-9965.EPI-21-0296. Epub ahead of print.
    • The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
    • Kershaw V, Hickey I, Wyld L, Jha S.
    • Eur J Obstet Gynecol Reprod Biol. 2021 Aug 8;265:7-17. doi: 10.1016/j.ejogrb.2021.08.001. Epub ahead of print.
    • Review
    • The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
    • Eoh KJ, Park EY, Chang YJ, Ha HI, Hong J, Huang D, Nam EJ, Lim MC.
    • Gynecol Oncol. 2021 Jul 22:S0090-8258(21)00590-4. doi: 10.1016/j.ygyno.2021.07.028. Epub ahead of print.
    • Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
    • Schrijver LH, Antoniou AC, Olsson H, Mooij TM, Roos-Blom MJ, Azarang L, Adlard J, Ahmed M, Barrowdale D, Davidson R, Donaldson A, Eeles R, Evans DG, Frost D, Henderson A, Izatt L, Ong KR, Bonadona V, Coupier I, Faivre L, Fricker JP, Gesta P, van Engelen K, Jager A, Menko FH, Mourits MJE, Singer CF, Tan YY, Foretova L, Navratilova M, Schmutzler RK, Ellberg C, Gerdes AM, Caldes T, Simard J, Olah E, Jakubowska A, Rantala J, Osorio A, Hopper JL, Phillips KA, Milne RL, Beth Terry M, Noguès C, Engel C, Kast K, Goldgar DE, van Leeuwen FE, Easton DF, Andrieu N, Rookus MA; Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International BRCA1/2 Carrier Cohort Study.
    • Am J Obstet Gynecol. 2021 Jul;225(1):51.e1-51.e17. doi: 10.1016/j.ajog.2021.01.014. Epub 2021 Jan 22.
    • Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    • Darelius A, Kristjansdottir B, Dahm-Kähler P, Strandell A.
    • Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714. Epub ahead of print.
    • An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    • Kotsopoulos J, Kim SJ, Armel S, Bordeleau L, Foulkes WD, McKinnon W, Panchal S, Cohen SA, Sun S, Sun P, McKetton L, Troyer AK, Narod SA.
    • Cancer. 2021 Jun 2. doi: 10.1002/cncr.33654. Epub ahead of print.
    • Lifestyle Characteristics in Women Carriers of BRCA Mutations: Results From an Italian Trial Cohort.
    • Bruno E, Oliverio A, Paradiso A, Daniele A, Tommasi S, Terribile DA, Filippone A, Digennaro M, Pilato B, Danza K, Guarino D, Rossi C, Rossi MM, Venturelli E, Giussani M, Peissel B, Pasanisi P.
    • Clin Breast Cancer. 2021 Jun;21(3):e168-e176. doi: 10.1016/j.clbc.2020.11.002. Epub 2020 Nov 10.
    • Did Breastfeeding my Daughter Reduce my Ovarian Cancer Risk?
    • Haarlander T.
    • FORCE. Blog. 2021 May 3.

    Research news: Study: Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations. (FORCE. XRAY.)

    Original research:

    Hereditary Ovarian Cancer Clinical Study Group. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.

    • Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
    • Huber D, Seitz S, Kast K, Emons G, Ortmann O.
    • J Cancer Res Clin Oncol. 2021 Apr 22. doi: 10.1007/s00432-021-03629-z. Epub ahead of print.
    • Fertility preservation in patients with BRCA mutations or Lynch syndrome.
    • Corrado G, Marchetti C, Trozzi R, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2021 Mar;31(3):332-338. doi: 10.1136/ijgc-2020-002071.

    Letter:

    Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers.

    Letter, Reply:

    Response to: Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers.

    • Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers.
    • Grill S, Yahiaoui-Doktor M, Basrai M, Struck J, Schulte J, Berling-Ernst A, Engel C, Ullrich M, Lammert J, Bischoff SC, Schmidt T, Niederberger U, Chronas D, Rhiem K, Schmutzler R, Halle M, Kiechle M.
    • Breast Cancer Res Treat. 2021 Feb 4. doi: 10.1007/s10549-020-06070-x. Epub ahead of print.
    • Study: Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations.
    • [No author given]
    • FORCE. XRAY. 2021 Jan 28.

    Original research:

    Hereditary Ovarian Cancer Clinical Study Group. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.

    Blog post: Did Breastfeeding my Daughter Reduce my Ovarian Cancer Risk? (FORCE. Blog.)

    • A Mediterranean Dietary Intervention in Female Carriers of BRCA Mutations: Results from an Italian Prospective Randomized Controlled Trial.
    • Bruno E, Oliverio A, Paradiso AV, Daniele A, Tommasi S, Tufaro A, Terribile DA, Magno S, Filippone A, Venturelli E, Morelli D, Baldassari I, Cravana ML, Manoukian S, Pasanisi P.
    • Cancers (Basel). 2020 Dec 11;12(12):3732. doi: 10.3390/cancers12123732.
    • Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    • Kotsopoulos J, Gronwald J, McCuaig JM, Karlan BY, Eisen A, Tung N, Bordeleau L, Senter L, Eng C, Couch F, Fruscio R, Weitzel JN, Olopade O, Singer CF, Pal T, Foulkes WD, Neuhausen SL, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2020 Dec;159(3):820-826. doi: 10.1016/j.ygyno.2020.09.037. Epub 2020 Sep 30.

    Research news: Study: Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations. (FORCE. XRAY.)

    Blog post: Did Breastfeeding my Daughter Reduce my Ovarian Cancer Risk? (FORCE. Blog.)

    • BRCA1/2 Variants and Metabolic Factors: Results From a Cohort of Italian Female Carriers.
    • Oliverio A, Bruno E, Colombo M, Paradiso A, Tommasi S, Daniele A, Terribile DA, Magno S, Guarino D, Manoukian S, Peissel B, Radice P, Pasanisi P.
    • Cancers (Basel). 2020 Nov 30;12(12):E3584. doi: 10.3390/cancers12123584.
    • Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review.
    • Huber D, Seitz S, Kast K, Emons G, Ortmann O.
    • Arch Gynecol Obstet. 2020 Jul 27. doi: 10.1007/s00404-020-05690-4. Epub ahead of print.
    • Diet, weight management, physical activity and Ovarian & Breast Cancer Risk in women with BRCA1/2 pathogenic Germline gene variants: systematic review.
    • Coletta AM, Peterson SK, Gatus LA, Krause KJ, Schembre SM, Gilchrist SC, Arun B, You YN, Rodriguez-Bigas MA, Strong LL, Lu KH, Basen-Engquist K.
    • Hered Cancer Clin Pract. 2020 Mar 7;18:5. doi: 10.1186/s13053-020-0137-1. eCollection 2020.
    • Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.
    • Huber D, Seitz S, Kast K, Emons G, Ortmann O.
    • Arch Gynecol Obstet. 2020 Mar 5. doi: 10.1007/s00404-020-05458-w. [Epub ahead of print]
    • Review
    • MUTATIONS OF GENES BRCA1 AND BRCA2 IN WOMEN WITH OVARIAN CANCER EXPOSED TO FACTORS OF CHORNOBYL NUCLEAR ACCIDENT.
    • Rybchenko LA, Poluben LO, Bychkova GM, Stephanovych GV, Klymenko SV.
    • Probl Radiac Med Radiobiol. 2019 Dec;24:455-464. doi: 10.33145/2304-8336-2019-24-455-464.
    • Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review.
    • Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T.
    • Fertil Steril. 2019 Oct 3. pii: S0015-0282(19)31982-X. doi: 10.1016/j.fertnstert.2019.07.1349. [Epub ahead of print]
    • Review
    • Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review.
    • Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T.
    • Gynecol Oncol. 2019 Aug 22. pii: S0090-8258(19)31333-2. doi: 10.1016/j.ygyno.2019.06.017. [Epub ahead of print]
    • Review
    • Combined hormonal contraceptives in BRCA gene mutation carriers: why not?
    • Grandi G, Sammarini M, Chiara Del Savio M, Toss A, Facchinetti F.
    • Eur J Contracept Reprod Health Care. 2019 Jul 30:1-3. doi: 10.1080/13625187.2019.1647335. [Epub ahead of print]
    • Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
    • Armstrong AC, Clay V.
    • Future Oncol. 2019 Jul 15. doi: 10.2217/fon-2018-0067. [Epub ahead of print]
    • Review
    • Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
    • Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arnold N, Arun BK, Ausems MGEM, Azzollini J, Barrowdale D, Barwell J, Benitez J, Białkowska K, Bonadona V, Borde J, Borg A, Bradbury AR, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Carter J, Chiquette J, Chung WK, Claes KBM, Collée JM, Collonge-Rame MA, Couch FJ, Daly MB, Delnatte C, Diez O, Domchek SM, Dorfling CM, Eason J, Easton DF, Eeles R, Engel C, Evans DG, Faivre L, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Gehrig A, Glendon G, Godwin AK, Gómez Garcia EB, Hamann U, Hauke J, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, Janavicius R, John EM, Karlan BY, Kets CM, Laitman Y, Lázaro C, Leroux D, Lester J, Lesueur F, Loud JT, Lubiński J, Łukomska A, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Mouret-Fourme E, Nathanson KL, Nehoray B, Neuhausen SL, Nevanlinna H, Nielsen FC, Offit K, Olah E, Ong KR, Oosterwijk JC, Ottini L, Parsons MT, Peterlongo P, Pfeiler G, Pradhan N, Radice P, Ramus SJ, Rantala J, Rennert G, Robson M, Rodriguez GC, Salani R, Scheuner MT, Schmutzler RK, Shah PD, Side LE, Simard J, Singer CF, Steinemann D, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Terry MB, Thomassen M, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Venat-Bouvet L, Vierstraete J, Wagner G, Walker L, Weitzel JN, Yannoukakos D; KConFab Investigators; HEBON Investigators; GEMO Study Collaborators; EMBRACE Collaborators, Antoniou AC, Goldgar DE, Olopade OI, Chenevix-Trench G, Rebbeck TR, Huo D; CIMBA.
    • Br J Cancer. 2019 Jun 19. doi: 10.1038/s41416-019-0492-8. [Epub ahead of print]
    • [Additional non-contraceptive effects of contraception: CNGOF Contraception Guidelines].
    • Amat L, Bulach A, Leclercq M, Mesrine S, Scheffler F, Sperandeo D, Scheffler M.
    • Gynecol Obstet Fertil Senol. 2018 Dec;46(12):883-888. doi: 10.1016/j.gofs.2018.10.013. Epub 2018 Nov 7.
    • Review, [Article in French]
    • The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.
    • Ko KP, Kim SJ, Huzarski T, Gronwald J, Lubinski J, Lynch HT, Armel S, Park SK, Karlan B, Singer CF, Neuhausen SL, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.
    • Int J Cancer. 2018 Jun 1;142(11):2263-2272. doi: 10.1002/ijc.31257. Epub 2018 Jan 25.
    • Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
    • Park JS, Lee ST, Han JW, Kim TI, Nam EJ, Park HS.
    • Clin Breast Cancer. 2018 Feb 20. pii: S1526-8209(17)30785-1. doi: 10.1016/j.clbc.2018.02.007. [Epub ahead of print]
    • Self-compassion, physical fitness and climacteric symptoms in oophorectomized BRCA1/2 mutation carriers.
    • Arts-de Jong M, van Westerop LL, Hoogerbrugge N, Massuger LF, Maas AH, van Beek MH, de Hullu JA.
    • Maturitas. 2018 Feb;108:13-17. doi: 10.1016/j.maturitas.2017.11.002. Epub 2017 Nov 3.
    • Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis.
    • Grill S, Yahiaoui-Doktor M, Dukatz R, Lammert J, Ullrich M, Engel C, Pfeifer K, Basrai M, Siniatchkin M, Schmidt T, Weisser B, Rhiem K, Ditsch N, Schmutzler R, Bischoff SC, Halle M, Kiechle M.
    • Arch Gynecol Obstet. 2017 Dec;296(6):1135-1144. doi: 10.1007/s00404-017-4546-y. Epub 2017 Oct 3.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Introduction. Risk Factors for Ovarian Cancer.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • A Class of Environmental and Endogenous Toxins Induces BRCA2 Haploinsufficiency and Genome Instability.
    • Tan SLW, Chadha S, Liu Y, Gabasova E, Perera D, Ahmed K, Constantinou S, Renaudin X, Lee M, Aebersold R, Venkitaraman AR.
    • Cell. 2017 Jun 1;169(6):1105-1118.e15. doi: 10.1016/j.cell.2017.05.010.

    Preview, Research news:

    Aldehydes Pose a Threat to BRCA2 Mutation Carriers.

    Research news:

    Aldehydes Promote BRCA2 Haploinsufficiency and Genomic Instability.

    Research report, Commentary:

    Thwarting endogenous stress: BRCA protects against aldehyde toxicity.

    • [Reflections on treatments for infertility and the possible occurrence of ovarian carcinomas.]
    • Ferranti G, Prosperi Porta R, La Rosa VL, Vitale SG, Laganà AS.
    • Recenti Prog Med. 2017 Mar;108(3):136-140. doi: 10.1701/2656.27236.
    • Commentary, [Article in Italian]
    • BRCA2: a grown-up cancer susceptibility gene.
    • Foulkes WD, Sugano K.
    • Endocr Relat Cancer. 2016 Oct;23(10):E1-E3.

    Review:

    BRCA2 functions: from DNA repair to replication fork stabilization.

    Review:

    Defects in homologous recombination repair behind the human diseases: FA and HBOC.

    Review:

    Synthetic lethality: the road to novel therapies for breast cancer.

    Review:

    Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

    Review:

    Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.

    • Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.
    • Milne RL, Antoniou A.
    • Endocr Relat Cancer. 2016 Oct;23(10):T69-T84. Epub 2016 Aug 15.

    Introductory article, Editorial:

    BRCA2: a grown-up cancer susceptibility gene.

    • Effects of lifestyle intervention in BRCA1/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trial.
    • Kiechle M, Engel C, Berling A, Hebestreit K, Bischoff SC, Dukatz R, Siniatchkin M, Pfeifer K, Grill S, Yahiaoui-Doktor M, Kirsch E, Niederberger U, Enders U, Löffler M, Meindl A, Rhiem K, Schmutzler R, Erickson N, Halle M.
    • Trials. 2016 Jul 29;17:368. doi: 10.1186/s13063-016-1504-0.
    • Should women at high risk for cancer use oral contraceptive pills?
    • Moorman PG.
    • Per Med. 2015 Nov;12(6):533-535. doi: 10.2217/pme.15.36. Epub 2015 Nov 3.
    • Editorial
    • [Breast and ovarian cancer due to BRCA1&2 hereditary cancer predisposition syndrome and reproduction: Literature review.]
    • Jégu M, Der AS, Morcel K, Abadie C, Fritel X, Levêque J.
    • J Gynecol Obstet Biol Reprod (Paris). 2015 Jan;44(1):10-17. doi: 10.1016/j.jgyn.2014.10.011. Epub 2014 Nov 18.
    • Review, [Article in French]
    • Use of fertility drugs and risk of ovarian cancer.
    • Diergaarde B, Kurta ML.
    • Curr Opin Obstet Gynecol. 2014 Jun;26(3):125-9. doi: 10.1097/GCO.0000000000000060.
    • Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.
    • Friebel TM, Domchek SM, Rebbeck TR.
    • J Natl Cancer Inst. 2014 Jun;106(6):dju091. doi: 10.1093/jnci/dju091.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: chemoprevetion for ovarian cancer

    News: Study Identifies Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. (The ASCO Post)

    • Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry.
    • Ferris JS, Daly MB, Buys SS, Genkinger JM, Liao Y, Terry MB.
    • Br J Cancer. 2014 Feb 18;110(4):1074-80. doi: 10.1038/bjc.2013.803. Epub 2014 Jan 7.
    • Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
    • Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER.
    • J Clin Oncol. 2013 Nov 20;31(33):4188-98. doi: 10.1200/JCO.2013.48.9021. Epub 2013 Oct 21.
    • Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study.
    • Rice MS, Murphy MA, Vitonis AF, Cramer DW, Titus LJ, Tworoger SS, Terry KL.
    • Int J Cancer. 2013 Nov 15;133(10):2415-21. doi: 10.1002/ijc.28249. Epub 2013 Jul 9.
    • Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers.
    • Primas H, Kroiss R, Kalteis K, Rappaport C, Muhr D, Primas C, Kubista E, Horvat R, Oefner P, Singer C, Wagner And The Austrian Hereditary Breast And Ovarian Cancer Group T.
    • Eur J Cancer Prev. 2012 Mar;21(2):199-204. doi: 10.1097/CEJ.0b013e32834c9b22.